118 related articles for article (PubMed ID: 29806152)
1. Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-β/SMAD signalling pathway.
Li J; Wang S; Qin F; Zhu M; You X; Wu C; Fu F; Yuan J
Andrologia; 2018 Sep; 50(7):e13051. PubMed ID: 29806152
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-29b attenuates fibrosis in a rat model of Peyronie's disease.
Candido P; Pimenta R; Maluf FC; Chiovatto C; Romão P; Baldavira CM; Ghazarian V; Camargo JA; Guimarães VR; Santos GAD; Silva IA; Nascimento B; Hallak J; Capelozzi VL; Srougi M; Nahas WC; Viana NI; Leite KR; Reis ST
Andrology; 2024 Jun; ():. PubMed ID: 38925608
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve-injured rats.
Hannan JL; Kutlu O; Stopak BL; Liu X; Castiglione F; Hedlund P; Burnett AL; Bivalacqua TJ
J Sex Med; 2014 Jun; 11(6):1442-51. PubMed ID: 24636283
[TBL] [Abstract][Full Text] [Related]
4. Microvesicles-delivering Smad7 have advantages over microvesicles in suppressing fibroblast differentiation in a model of Peyronie's disease.
Wang W; Wan F; Yu T; Wu S; Cui X; Xiang C; Li M; Liu Q; Lin C
BMC Biotechnol; 2024 Jun; 24(1):40. PubMed ID: 38849776
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel rabbit model of Peyronie's disease.
Gundogdu G; Nguyen T; Namasivayam A; Starek S; Gelman J; Mauney JR
Int J Impot Res; 2024 May; 36(3):269-274. PubMed ID: 36782023
[TBL] [Abstract][Full Text] [Related]
6. TGF-β1 induces formation of TSG-6-enriched extracellular vesicles in fibroblasts which can prevent myofibroblast transformation by modulating Erk1/2 phosphorylation.
Ilg MM; Bustin SA; Ralph DJ; Cellek S
Sci Rep; 2024 May; 14(1):12389. PubMed ID: 38811625
[TBL] [Abstract][Full Text] [Related]
7. Temporal gene signature of myofibroblast transformation in Peyronie's disease: first insights into the molecular mechanisms of irreversibility.
Ilg MM; Harding S; Lapthorn AR; Kirvell S; Ralph DJ; Bustin SA; Ball G; Cellek S
J Sex Med; 2024 Mar; 21(4):278-287. PubMed ID: 38383071
[TBL] [Abstract][Full Text] [Related]
8. Fibroproliferative disorders and diabetes: Understanding the pathophysiologic relationship between Peyronie's disease, Dupuytren disease and diabetes.
Gelbard MK; Rosenbloom J
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00195. PubMed ID: 33855203
[TBL] [Abstract][Full Text] [Related]
9. Rat as an animal model for Peyronie's disease research: a review of current methods and the peer-reviewed literature.
Chung E; De Young L; Brock GB
Int J Impot Res; 2011; 23(6):235-41. PubMed ID: 21776004
[TBL] [Abstract][Full Text] [Related]
10. The pathogenic role of the immune system in erectile dysfunction and Peyronie's disease: focusing on immunopathophysiology and potential therapeutic strategies.
Giagulli VA; Lisco G; De Tullio A; Guastamacchia E; Triggiani V; Jirillo E
Sex Med Rev; 2024 Mar; 12(2):210-220. PubMed ID: 38196188
[TBL] [Abstract][Full Text] [Related]
11. Multimodal treatments based on Tadalafil during acute phase of Peyronie's disease: experience at two referral academic centers.
Dell'Atti L; Slyusar V; Cambise C
Ir J Med Sci; 2024 Jun; ():. PubMed ID: 38861101
[TBL] [Abstract][Full Text] [Related]
12. US Imaging in Peyronie's Disease.
Kalokairinou K; Konstantinidis C; Domazou M; Kalogeropoulos T; Kosmidis P; Gekas A
J Clin Imaging Sci; 2012; 2():63. PubMed ID: 23230545
[TBL] [Abstract][Full Text] [Related]
13. Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie's disease: a retrospective analysis of 309 cases.
Paulis G; Romano G; Paulis A
Res Rep Urol; 2016; 8():95-103. PubMed ID: 27486570
[TBL] [Abstract][Full Text] [Related]
14. Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease.
Dell'Atti L
Urol Ann; 2015; 7(3):345-9. PubMed ID: 26229323
[TBL] [Abstract][Full Text] [Related]
15. Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up.
Al-Thakafi S; Al-Hathal N
Transl Androl Urol; 2016 Jun; 5(3):280-9. PubMed ID: 27298774
[TBL] [Abstract][Full Text] [Related]
16. Evaluating treatment pathways for Peyronie's disease utilizing the TriNetX research registry.
Ghosh A; Leong JY; Foss H; Ebbott D; Prebay Z; Li M; Chung PH
Int J Impot Res; 2024 Apr; 36(2):168-170. PubMed ID: 38160222
[No Abstract] [Full Text] [Related]
17. Data vs Dogma in Peyronie's Disease.
Terlecki RP; Rasper AM
Int Braz J Urol; 2016; 42(6):1058-1061. PubMed ID: 27813380
[No Abstract] [Full Text] [Related]
18. Ultrasound Elastography as a Diagnostic Tool for Peyronie's Disease: A State-of-the-Art Review.
Paulis G; De Giorgio G; Paulis A
Diagnostics (Basel); 2024 Mar; 14(6):. PubMed ID: 38535085
[TBL] [Abstract][Full Text] [Related]
19. Advancements and challenges in Peyronie's disease: a personal journey and current perspectives.
Levine LA
Int J Impot Res; 2024 Apr; 36(2):105-106. PubMed ID: 38332191
[No Abstract] [Full Text] [Related]
20. Commentary on: Safety and feasibility of percutaneous needle tunneling with platelet-rich plasma injections for Peyronie's disease in the outpatient setting: a pilot study.
Şahin A; Gül M
Int J Impot Res; 2024 Apr; 36(2):162-163. PubMed ID: 38066177
[No Abstract] [Full Text] [Related]
[Next] [New Search]
